Ardent Health, Inc. (ARDT)
| Market Cap | 1.32B -36.5% |
| Revenue (ttm) | 6.43B +6.7% |
| Net Income | 134.28M -40.2% |
| EPS | 0.95 -42.0% |
| Shares Out | 143.35M |
| PE Ratio | 9.71 |
| Forward PE | 7.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,671 |
| Open | 9.19 |
| Previous Close | 9.21 |
| Day's Range | 9.08 - 9.39 |
| 52-Week Range | 8.07 - 15.48 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 12.50 (+35.43%) |
| Earnings Date | May 5, 2026 |
About ARDT
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free... [Read more]
Financial Performance
In 2025, Ardent Health's revenue was $6.32 billion, an increase of 6.01% compared to the previous year's $5.97 billion. Earnings were $135.81 million, a decrease of -35.43%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ARDT stock is "Buy." The 12-month stock price target is $12.5, which is an increase of 35.43% from the latest price.
News
Ardent Health Transcript: AGM 2026
The meeting established a quorum and proceeded with the election of eleven directors, approval of executive compensation, and ratification of the independent auditor, with all proposals passing by majority or plurality vote.
Ardent Health partners with Fujifilm to deliver Synapse imaging solutions
Ardent Health (ARDT) has partnered with Fujifilm Healthcare Americas Corporation to implement its Synapse enterprise imaging solutions across Ardent’s acute care hospital footprint across six states. ...
Ardent Health and Fujifilm Partner to Deliver Synapse Enterprise Imaging Across Radiology and Cardiology Throughout All Facilities
BRENTWOOD, Tenn. & LEXINGTON, Mass.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., has partnered with FUJIFILM H...
Ardent Health Transcript: Bank of America Global Healthcare Conference 2026
Leaders outlined a three-part growth strategy focused on margin improvement, regional and outpatient expansion, and selective M&A. Q1 saw solid adjusted admissions growth, strong outpatient performance, and stabilized denial rates. The IMPACT program and AI initiatives are driving margin gains, with a mid-teens EBITDA margin targeted over the next few years.
Ardent Health price target raised to $13.50 from $13 at UBS
UBS raised the firm’s price target on Ardent Health (ARDT) to $13.50 from $13 and keeps a Buy rating on the shares.
Ardent Health Earnings Call Transcript: Q1 2026
Revenue rose 7% and Adjusted EBITDA grew 26% year-over-year, driven by cost discipline, outpatient growth, and IMPACT Program savings. Guidance for 2026 is reaffirmed, with continued focus on margin expansion, ambulatory investment, and operational efficiency.
Ardent Health Earnings release: Q1 2026
Ardent Health released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Ardent Health Slides: Q1 2026
Ardent Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Ardent Health Quarterly report: Q1 2026
Ardent Health has published its Q1 2026 quarterly earnings report on May 6, 2026.
Ardent Health Reports First Quarter 2026 Results
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today a...
Ardent Health to Participate in the Bank of America 2026 Healthcare Conference
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participat...
Ardent Health Announces First Quarter 2026 Results Conference Call and Webcast Date
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its first qua...
Ardent Health price target lowered to $13 from $15 at Guggenheim
Guggenheim lowered the firm’s price target on Ardent Health (ARDT) to $13 from $15 and keeps a Buy rating on the shares.
Ardent Health Proxy statement: Proxy filing
Ardent Health filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Ardent Health Proxy statement: Proxy filing
Ardent Health filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Ardent Health Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Strong 2025 growth was driven by admissions and outpatient expansion, but payer denials and professional fee inflation remain key headwinds for 2026. AI and operational initiatives are improving efficiency, while joint ventures and ambulatory investments support long-term growth. Margin pressures from exchange subsidy loss and payer dynamics are closely monitored.
Ardent Health Transcript: Leerink Global Healthcare Conference 2026
Investments in AI and digital platforms are driving operational transformation, with early productivity gains and plans for broader rollout. Financial headwinds from subsidy expirations and payer denials are being managed through cautious assumptions and technology-driven improvements. Outpatient and ASC expansion, joint ventures, and workforce initiatives are key growth drivers.
Ardent Health price target lowered to $15 from $16 at Leerink
Leerink lowered the firm’s price target on Ardent Health (ARDT) to $15 from $16 and keeps an Outperform rating on the shares. The firm says the company’s Q4 results were…
Ardent Health price target lowered to $13 from $14 at UBS
UBS analyst AJ Rice lowered the firm’s price target on Ardent Health (ARDT) to $13 from $14 and keeps a Buy rating on the shares.
Ardent Health Earnings Call Transcript: Q4 2025
Record 2025 results with 6% revenue and 9% adjusted EBITDA growth, driven by IMPACT program savings and technology initiatives. 2026 guidance reflects prudent assumptions amid industry headwinds, with margin expansion and further cost optimization expected.
Ardent Health Annual report: Q4 2025
Ardent Health has published its Q4 2025 annual report on March 5, 2026.
Ardent Health Earnings release: Q4 2025
Ardent Health released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Ardent Health Slides: Q4 2025
Ardent Health has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Ardent Health reports Q4 EPS 32c, consensus 35c
Reports Q4 revenue $1.605B, consensus $1.63B. “I’m pleased with tangible progress from the deliberate, measurable actions we took during the fourth quarter to mitigate the payor denial and professiona...
Ardent Health sees FY26 EPS $0.90-$1.27, consensus $1.35
Sees FY26 revenue $6.4B-$6.7B, consensus $6.64B